PPD Names Daniel Darazsdi as Chief Financial Officer
PPD, Inc. has announced that Daniel G. Darazsdi has been appointed chief financial officer. He will assume his position on October 1.
Mr. Darazsdi, 47, comes to PPD after 25 years with Honeywell International, a $34 billion diversified technology and manufacturing leader, where he most recently served as vice president and CFO of finance transformation and operations. Over the years at Honeywell, he was CFO of the company’s global specialty materials business segment and held a variety of leadership roles in finance including business analysis and planning, corporate treasury, financial planning and reporting, and process improvement. In addition, Mr. Darazsdi provided finance, information technology and business development leadership for Honeywell’s performance polymers strategic business unit; served in Hong Kong as vice president for the company’s Asia-Pacific finance and information technology organizations across 12 countries; and spent several years in Sydney, Australia, directing finance and administration for the company’s operations in that country.
“Dan Darazsdi is a seasoned professional whose career portfolio includes extensive experience in business unit finance, corporate treasury and international management,” said Fred Eshelman, chief executive officer of PPD. “We are delighted he is joining our organization and look forward to the addition of his strategic leadership to our executive team.”
Mr. Darazsdi holds a bachelor of business administration degree from James Madison University, is a graduate of the Honeywell Financial Leadership Development Program and is a certified management accountant.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 28 countries and more than 9,700 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.